Vera S Hengeveld, Natasja Lammers, Mattienne R van der Kamp, Job van der Palen, Bernard J Thio
{"title":"单剂量二丙酸倍氯米松的反应能否预测儿童运动性支气管收缩长期治疗的结果?","authors":"Vera S Hengeveld, Natasja Lammers, Mattienne R van der Kamp, Job van der Palen, Bernard J Thio","doi":"10.1111/pai.13808","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Exercise-induced bronchoconstriction (EIB) is a frequent and highly specific symptom of childhood asthma. Inhaled corticosteroids (ICS) are the mainstay of controller therapy for EIB and asthma; however, a proportion of asthmatic children and adolescents is less responsive to ICS. We hypothesized that a single dose response to ICS could function as a predictor for individual long-term efficacy of ICS.</p><p><strong>Objective: </strong>To assess the predictive value of the bronchoprotective effect of a single-dose beclomethasone dipropionate (BDP) against EIB for the bronchoprotective effect of 4 weeks of treatment, using an exercise challenge test (ECT).</p><p><strong>Methods: </strong>Thirty-two steroid-naïve children and adolescents aged 6 to 18 years with EIB were included in this prospective cohort study. They performed an ECT at baseline, after a single-dose BDP (200µg) and after 4 weeks of BDP treatment (100 µg twice daily) to assess EIB severity.</p><p><strong>Results: </strong>The response to a single-dose BDP on exercise-induced fall in FEV1 showed a significant correlation with the response on exercise-induced fall in FEV1 after 4 weeks of BDP treatment (r = .38, p = .004). A reduction in post-exercise fall in FEV1 of more than 8% after a single-dose BDP could predict BDP efficacy against EIB after 4 weeks of treatment with a positive predictive value of 100% (CI: 86.1-100%) and a negative predictive value of 29.4% (CI: 11.7%-53.7%).</p><p><strong>Conclusion: </strong>We found that the individual response to a single-dose BDP against EIB has a predictive value for the efficacy of long-term treatment with BDP. This could support clinicians in providing personalized management of EIB in childhood asthma.</p>","PeriodicalId":520742,"journal":{"name":"Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology","volume":" ","pages":"e13808"},"PeriodicalIF":4.5000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Can the response to a single dose of beclomethasone dipropionate predict the outcome of long-term treatment in childhood exercise-induced bronchoconstriction?\",\"authors\":\"Vera S Hengeveld, Natasja Lammers, Mattienne R van der Kamp, Job van der Palen, Bernard J Thio\",\"doi\":\"10.1111/pai.13808\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Exercise-induced bronchoconstriction (EIB) is a frequent and highly specific symptom of childhood asthma. Inhaled corticosteroids (ICS) are the mainstay of controller therapy for EIB and asthma; however, a proportion of asthmatic children and adolescents is less responsive to ICS. We hypothesized that a single dose response to ICS could function as a predictor for individual long-term efficacy of ICS.</p><p><strong>Objective: </strong>To assess the predictive value of the bronchoprotective effect of a single-dose beclomethasone dipropionate (BDP) against EIB for the bronchoprotective effect of 4 weeks of treatment, using an exercise challenge test (ECT).</p><p><strong>Methods: </strong>Thirty-two steroid-naïve children and adolescents aged 6 to 18 years with EIB were included in this prospective cohort study. They performed an ECT at baseline, after a single-dose BDP (200µg) and after 4 weeks of BDP treatment (100 µg twice daily) to assess EIB severity.</p><p><strong>Results: </strong>The response to a single-dose BDP on exercise-induced fall in FEV1 showed a significant correlation with the response on exercise-induced fall in FEV1 after 4 weeks of BDP treatment (r = .38, p = .004). A reduction in post-exercise fall in FEV1 of more than 8% after a single-dose BDP could predict BDP efficacy against EIB after 4 weeks of treatment with a positive predictive value of 100% (CI: 86.1-100%) and a negative predictive value of 29.4% (CI: 11.7%-53.7%).</p><p><strong>Conclusion: </strong>We found that the individual response to a single-dose BDP against EIB has a predictive value for the efficacy of long-term treatment with BDP. This could support clinicians in providing personalized management of EIB in childhood asthma.</p>\",\"PeriodicalId\":520742,\"journal\":{\"name\":\"Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology\",\"volume\":\" \",\"pages\":\"e13808\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/pai.13808\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/pai.13808","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:运动性支气管收缩(EIB)是儿童哮喘的一种常见且高度特异性的症状。吸入皮质类固醇(ICS)是EIB和哮喘的主要控制疗法;然而,有一部分患有哮喘的儿童和青少年对ICS的反应较差。我们假设对ICS的单剂量反应可以作为个体ICS长期疗效的预测因子。目的:采用运动激发试验(ECT),评价单剂量二丙酸倍氯米松(BDP)对EIB治疗4周后支气管保护作用的预测价值。方法:在这项前瞻性队列研究中纳入32名年龄在6至18岁的steroid-naïve儿童和青少年EIB患者。他们在基线、单剂量BDP(200µg)和BDP治疗4周(100µg,每天两次)后进行ECT,以评估EIB的严重程度。结果:单剂量BDP对运动诱导的FEV1下降的反应与BDP治疗4周后运动诱导的FEV1下降的反应具有显著相关性(r = 0.38, p = 0.004)。单剂量BDP治疗后运动后FEV1下降幅度超过8%,可以预测BDP治疗4周后对EIB的疗效,阳性预测值为100% (CI: 86.1-100%),阴性预测值为29.4% (CI: 11.7%-53.7%)。结论:我们发现单剂量BDP对EIB的个体反应对BDP长期治疗的疗效具有预测价值。这可以支持临床医生为儿童哮喘患者提供个性化的EIB管理。
Can the response to a single dose of beclomethasone dipropionate predict the outcome of long-term treatment in childhood exercise-induced bronchoconstriction?
Background: Exercise-induced bronchoconstriction (EIB) is a frequent and highly specific symptom of childhood asthma. Inhaled corticosteroids (ICS) are the mainstay of controller therapy for EIB and asthma; however, a proportion of asthmatic children and adolescents is less responsive to ICS. We hypothesized that a single dose response to ICS could function as a predictor for individual long-term efficacy of ICS.
Objective: To assess the predictive value of the bronchoprotective effect of a single-dose beclomethasone dipropionate (BDP) against EIB for the bronchoprotective effect of 4 weeks of treatment, using an exercise challenge test (ECT).
Methods: Thirty-two steroid-naïve children and adolescents aged 6 to 18 years with EIB were included in this prospective cohort study. They performed an ECT at baseline, after a single-dose BDP (200µg) and after 4 weeks of BDP treatment (100 µg twice daily) to assess EIB severity.
Results: The response to a single-dose BDP on exercise-induced fall in FEV1 showed a significant correlation with the response on exercise-induced fall in FEV1 after 4 weeks of BDP treatment (r = .38, p = .004). A reduction in post-exercise fall in FEV1 of more than 8% after a single-dose BDP could predict BDP efficacy against EIB after 4 weeks of treatment with a positive predictive value of 100% (CI: 86.1-100%) and a negative predictive value of 29.4% (CI: 11.7%-53.7%).
Conclusion: We found that the individual response to a single-dose BDP against EIB has a predictive value for the efficacy of long-term treatment with BDP. This could support clinicians in providing personalized management of EIB in childhood asthma.